

**REMARKS**

The claims have been amended above to clarify the nature of the claimed invention. Specifically, claim 49 has been amended to indicate that the claimed composition may comprise at least one anthrax antigen, and that the at least one anthrax antigen and the at least one mucosal adjuvant are in combination with a mucosal administration device. Dependent claims 50-54 have been amended to preserve antecedent basis with amended claim 49. Support for the new claims may be found throughout the specification of the PCT application as filed, for instance in original claim 1, and in paragraph 097. No prohibited new matter has been added by way of this amendment.


If the Examiner has any further questions relating to this Amendment or to the application in general, he or she is respectfully requested to contact the undersigned by telephone so that allowance of the present application may be expedited.

Dated: April 17, 2007

COOLEY GODWARD KRONISH LLP  
ATTN: Patent Group  
1200 19<sup>th</sup> Street, NW, 5<sup>th</sup> Floor  
Washington, DC 20036  
Tel: (202) 842-7800  
Fax: (202) 842-7899

Respectfully submitted,  
**COOLEY GODWARD KRONISH LLP**

By:

  
Bonnie Weiss McLeod  
Reg. No. 43,255